CA-SYNTERACTHCR
10.11.2016 13:02:35 CET | Business Wire | Press release
Executives from SynteractHCR , a full-service, international contract research organization (CRO), are continuing to exhibit and speak at various industry conferences around the globe in November. The events include World Immunotherapy Congress, World Orphan Drug Congress Europe and Partnerships in Clinical Trials Europe. Each event brings together thought leaders from biotech, pharma and related industries to network and stay abreast of new developments and best practices.
The World Immunotherapy Congress , Nov. 14-16 at Congress Center in Basel, Switzerland, offers experts multiple opportunities to discuss the promising developments in immunotherapy, including immune checkpoint inhibitors and cell therapy. SynteractHCR will exhibit in booth #28 and will have clinical trial experts available to meet with companies that are focused on developing oncology and other therapeutic indication trials using immunotherapy techniques. To make an appointment to meet with SynteractHCR, contact Volker Knorz: Volker.Knorz@SynteractHCR.com .
The World Orphan Drug Congress Europe 2016 will be held Nov. 15-17 in Brussels, where Dr. Stephan de la Motte, chief medical advisor for SynteractHCR, will host two roundtables: the first on “Sharing Practical Insights on the Planning and Execution of Orphan Drug Clinical Trials ” at 11:30 am on Wed., Nov. 16th and the second on the same topic (time, date). Clients and others who might like to meet with the team at World Orphan may contact Alexandre Wallard: Alexandre.Wallard@SynteractHCR.com .
At the Partnerships in Clinical Trials Europe (PCT) event, Vice President for Global Medical and Regulatory Affairs Dr. Martine Dehlinger-Kremer will present : “Planning for the Impact of the New EU Clinical Trials Regulation and the Implications of the UK Brexit” from 11:25 a.m. – 12:00 p.m. EDT on Thursday, November 17th . Attendees will leave the presentation prepared for the upcoming EU Regulation and will better understand how Brexit may affect the new regulation. SynteractHCR will exhibit in booth #173.
Lastly, clinical trial experts from the company will also attend BVMA in Munich from Nov. 24-25th , 2016. Those who wish to meet with the team at either PCT or BVMA, or with Dr. Dehlinger-Kremer, may contact Xavier Morillon: Xavier.Morillon@SynteractHCR.com .
See SynteractHCR's full schedule of events and follow its social channels on LinkedIn and Twitter for live updates during all conferences.
About SynteractHCR
SynteractHCR is a full-service contract research organization with a successful two-decade track record supporting biotechnology, medical device and pharmaceutical companies in all phases of clinical development. SynteractHCR has conducted Phase I-IV studies on six continents and 60 countries, offering expertise across multiple therapeutic areas, with notable depth in oncology, immunotherapy, CNS, infectious disease, endocrinology, cardiovascular and respiratory, among other indications. With its “Shared Work – Shared Vision ” philosophy, SynteractHCR provides customized services collaboratively and cost effectively, ensuring on-time delivery of quality data to help bring tomorrow’s treatments to patients.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161110005548/en/
Contact:
SynteractHCR
Beth Walsh, 760-230-2424
Beth@clearpointagency.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Gurobi’s Decision Intelligence Summit Comes to Prague13.10.2026 09:00:00 CEST | Press release
The Gurobi Summit EMEA returns October 13–14 to showcase why optimization is the AI that drives trusted decisions. Gurobi Optimization, LLC, the leader in decision intelligence technology, today unveiled the 2026 Gurobi Decision Intelligence Summit (“Gurobi Summit”) EMEA, taking place October 13–14 in Prague. Following the U.S. version of the event, which took place September 22-23 in Las Vegas, attendees in the EMEA region will gather at the Fantova Budova for two days of innovative use case presentations, in-depth trainings, and expert-led panels. Sessions will highlight how optimization is the most suitable form of AI for delivering actionable, defensible decisions, and how generative AI can break down barriers to entry and help more users apply optimization’s full potential. This year’s presentations will include speakers from ALDI, Dutch Railways, Ryanair Labs, SAP, Skydance, and more. Several of Gurobi’s partners will also be present to showcase their solutions and expertise. In
YouHodler Italy Authorised by CONSOB as a Crypto-Asset Service Provider Under MiCA13.10.2026 09:00:00 CEST | Press release
Authorisation covers custody, exchange of crypto-assets for funds and for other crypto-assets, execution of orders and transfer services YouHodler Italy S.r.l., announces that CONSOB, after hearing the Bank of Italy, has authorised it as a crypto-asset service provider (CASP) under Regulation (EU) 2023/1114 (MiCA) and Legislative Decree 129/2024, by resolution no. 24156 of 8 October 2026. The authorisation covers five services: custody and administration of crypto-assets on behalf of clients; exchange of crypto-assets for funds; exchange of crypto-assets for other crypto-assets; execution of orders on behalf of clients; and transfer services for crypto-assets on behalf of clients. With the authorisation, YouHodler Italy serves clients in Italy as a supervised firm under MiCA's client protections: segregation of client crypto-assets, governance and security requirements, pre-contractual information and complaints handling. The company plans to extend its services to all 27 EU Member Sta
Manhattan Wins Kesko Mandate as Nordic Retail Giant Bets on Cloud-Native, AI-Driven Warehousing13.10.2026 09:00:00 CEST | Press release
The race to modernise Europe's grocery supply chains has entered a new phase, with Finnish retail group Kesko selecting ActiveWarehouse™ from leading supply chain and omnichannel commerce solutions provider Manhattan Associates Inc. (NASDAQ: MANH). The Nordic retail giant is replacing its grocery trade legacy warehouse management system with the industry’s leading, cloud-native warehouse management solution, including agentic AI capabilities delivered through ActiveAgents™ and Agent Foundry. For Finland’s second largest grocery brand, and one of the biggest in Northern Europe, the investment reflects the growing strategic importance of operational agility, as digital and physical retail become increasingly interconnected and a broader shift taking place across retail logistics more generally. The scale of Kesko’s grocery trade makes the project noteworthy in Finnish and European retail. In 2025, the division’s net sales amounted to EUR 6.5 billion, and its comparable operating profit w
Horizon3 Promotes Keith Poyser to General Manager, EMEA Following More Than 260% Regional Revenue Growth13.10.2026 09:00:00 CEST | Press release
Poyser built the EMEA team from eight to more than 110 employees and will lead the company’s next phase of expansion across the region. Horizon3 today announced the promotion of Keith Poyser to General Manager, EMEA. Previously Vice President, EMEA, Poyser will oversee the company’s next phase of growth and expansion across Europe, the Middle East and Africa. His promotion follows more than 260% regional revenue growth in the last fiscal year and the opening of Horizon3’s EMEA headquarters in Amsterdam. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261013365926/en/ Keith Poyser promoted to General Manager, EMEA following more than 260% regional revenue growth Since joining Horizon3 in September 2024, Poyser has recruited experienced talent and established a regional leadership bench, growing the EMEA team from eight to more than 110 employees. He has built a culture of trust, collaboration and accountability to support the
New Galderma Research Reveals More Than Half of Women Mistake Menopause-Related Skin Changes for Signs of Ageing13.10.2026 07:00:00 CEST | Press release
New clinical data identify optimized injectable aesthetics treatment protocol for menopause-induced skin changes 56% of women have experienced ‘The Menopausal Skin Misread’, admitting they first put menopause-related skin changes down to ageing, while fewer than a third (29%) recognized menopause as the cause1 A significant knowledge gap remains: one in two women are unaware that hormonal changes during perimenopause and menopause can affect the skin, and 82% agree that better understanding the difference between menopause-related skin changes and general ageing would help them feel more informed and in control of their skincare decisions1 New data from an investigator-initiated trial (IIT) led by Dr. Andreas Nikolis and supported by Galderma, demonstrated that a sequenced treatment approach using Restylane Skinboosters followed by Sculptra delivered significant improvements in skin hydration and remodeling across the face and décolletage in menopausal women, highlighting the value of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom